Ecnoglutide Dosage, half-life & reference guide
Also known as XW003 · XW004 · VRB-101 · Ecno
Reviewed 6 studiesEvidence: EstablishedPublished by PepVault
A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased". In its phase 3 obesity trial, the 2.4 mg dose took off about 13% at 40 weeks and about 15% at 48 weeks.
- Studied range
- 0.6–2.4 mgstarting dose 0.3 mg
- How often
- Weekly
- Half-life
- ~5.5 days
- Evidence
- ●●●
Established - Route
- SubQ injection
Studied in research — not a recommendation.
How it works.
Once-weekly GLP-1 receptor agonist, the same receptor as semaglutide, with one amino-acid change that is thought to favour the receptor's cAMP signal over the step that pulls the receptor into the cell, plus a fatty-acid chain for a long half-life. Developed by Sciwind Biosciences in China, where it was approved in 2026 for type 2 diabetes and for weight management; it is not FDA-approved. A weekly tablet form is in trials.
Commonly reported: Appetite control and early GI side effects, much as with semaglutide. It is not FDA-approved.
Half-life & active level
The half-life of Ecnoglutide is ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026).
Here's how a typical Ecnoglutide schedule accumulates over four weeks (one-compartment estimate).
An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.

Model. Individual results vary.
Where Ecnoglutide works.

Appetite & metabolism
In people. A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- Days–2 weeks
- Peak effect
- 48 weeks (phase 3, no plateau)
- Duration
- Ongoing
Day 1–28 · 0.3 mgRCT
A low first month
You're on 0.3 mg, the first step in ecnoglutide's diabetes trials. Commonly reported: appetite dropping within days. In those trials, GI side effects came mainly while the dose was stepping up and faded after.
The science
Phase 3 vs placebo in type 2 diabetes (Zhu 2026, Nat Commun; NCT05680155): "a slow dose-escalation regimen, starting at 0.3 mg ... with fixed double-dose increments every 4 weeks"; GI adverse events "mainly occurred in the dose escalation period and diminished over time".
Sources- Zhu et al. (2026)
Updated Nov 2026
Day 29–56 · 0.6 mgRCT
Doubling to 0.6 mg
You're at 0.6 mg, the second step, and one of the maintenance doses tested in type 2 diabetes. Commonly reported: a few queasy days after the step, then steadier appetite.
The science
In the type 2 diabetes trial, the 0.6 mg maintenance dose was reached at week 4 and 1.2 mg at week 8 (Zhu 2026). Pulse rose slightly on ecnoglutide, consistent with the GLP-1 class, and no severe hypoglycaemia was reported.
Sources- Zhu et al. (2026)
Updated Nov 2026
Any dayRCT
What Ecnoglutide is built on
Phase 1 and 2 trials, a phase 3 obesity trial of 664 people, and two phase 3 diabetes trials, one against dulaglutide. China approved it in 2026. It is not FDA-approved.
The science
Discovery: a GLP-1 analogue with Val8 and a lysine-30 fatty acid, cAMP-biased with less receptor internalisation (Guo 2023, Mol Metab). SLIMMER (Ji 2025; NCT05813795, sponsor Hangzhou Sciwind Biosciences). Type 2 diabetes: vs placebo (Zhu 2026, Nat Commun) and vs dulaglutide (He 2025, Lancet Diabetes Endocrinol). Approvals: China, January 2026 (type 2 diabetes) and March 2026 (weight management) (Shirley 2026, Drugs). Interaction studies: Chen 2026 (warfarin, metformin), Li 2026 (rosuvastatin, digoxin).
Sources- Guo et al. (2023)
- Ji et al. (SLIMMER) (2025)
- Zhu et al. (2026)
- He et al. (2025)
- Shirley (2026)
Updated Nov 2026
With BPC-157Community
Why people add BPC-157 to a GLP-1
GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.
The science
BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside ecnoglutide or any GLP-1 drug; the pairing comes from community reports.
Sources- Sikiric et al. (2018)
Updated Nov 2026
After week 8
Day 57–336 · 1.2 mgRCT
The lowest weight-loss dose
You're at 1.2 mg, the lowest dose in the obesity trial. That group lost about 9% of body weight by week 40, and about three in four lost at least 5%.
The science
SLIMMER (Ji 2025, Lancet Diabetes Endocrinol; 664 adults without diabetes, 36 centres in China): 1.2 mg −9.1% at week 40 vs +0.1% on placebo (difference −9.2%); 77% reached ≥5% loss vs 16% (treatment-policy estimand).
Sources- Ji et al. (SLIMMER) (2025)
Updated Nov 2026
Day 85–336 · 1.8 mgRCT
The middle dose
You're at 1.8 mg. In SLIMMER, that group lost about 11% by week 40, and 84% lost at least 5%.
The science
SLIMMER week 40: 1.8 mg −10.9% vs +0.1% on placebo (difference −11.1%); 84% reached ≥5% vs 16% (Ji 2025).
Sources- Ji et al. (SLIMMER) (2025)
Updated Nov 2026
Day 85–336 · 2.4 mgRCT
The top dose
You're at 2.4 mg, the highest dose in the obesity trial. That group lost about 13% by week 40 and about 15% by week 48, and was still losing. About two in three lost at least 15%.
The science
SLIMMER: 2.4 mg −13.2% at week 40 vs +0.1% (difference −13.3%), 87% ≥5% (Ji 2025). At week 48 (treatment-policy): −15.4% (placebo-adjusted −15.1%), 92.8% ≥5%, 79.6% ≥10%, 63.5% ≥15%, no plateau; liver fat −53.1% at week 40 in those starting at 8% or more (Sciwind, Mar-6-2026).
Sources- Ji et al. (SLIMMER) (2025)
- Sciwind (approval release) (2026)
Updated Nov 2026
Day 337+Clinical
A long-term medicine, not a course
Worth knowing before you stop: with GLP-1 drugs, coming off usually means regaining most of the loss within about a year and a half. Ecnoglutide hasn't been tested in a stopping trial, so this is the pattern of the class. Continue, taper or stop is a call for you and your clinician.
The science
A BMJ meta-analysis found that after stopping semaglutide or tirzepatide, about 9.9 kg came back within the first year, with weight projected back to baseline about 1.5 years after stopping (West 2026). A weight-maintenance trial of oral ecnoglutide (NCT07553299) was terminated early in 2026.
Sources- West et al. (2026)
Updated Nov 2026
Day 1 is the day you start it.
Phase 3 SLIMMER (Ji 2025, Lancet Diabetes Endocrinol), phase 3 in type 2 diabetes (Zhu 2026, Nat Commun; He 2025, Lancet Diabetes Endocrinol), approvals (Shirley 2026, Drugs), Sciwind release Mar-6-2026, interaction studies (Chen 2026; Li 2026). The Chinese label was not read.
Clinical trial data
Mixing and a typical run.
Example numbers
Reconstitution example
Reconstitute a 10 mg vial of Ecnoglutide with 2 mL of bacteriostatic water and a 0.3 mg dose is 6 units on a U-100 syringe, about 33 doses per vial.
- Vial
- 10 mg
- Water
- 2 mL
- Amount
- 0.3 mg
Draw to6 units
0.3 mL insulin syringe · 30 units
Run notes
- Cycle
- Used continuously, once weekly, in its trials: 40 to 48 weeks in obesity and up to 52 weeks in type 2 diabetes, with the dose doubled every 4 weeks up to the maintenance dose.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Once weekly SubQ, same day each week, in its trials. The diabetes trials started at 0.3 mg and doubled every 4 weeks (0.6 mg by week 4, 1.2 mg by week 8); the obesity trial used maintenance doses of 1.2, 1.8 and 2.4 mg. These are trial schedules; the Chinese label governs approved use there.
- Route
- SubQ injection
- Stacks
- BPC-157 (GI support)
Safety.
Common side effects
- Decreased appetite
- Diarrhea
- Nausea
- Abdominal bloating
- Weakness
Interactions
In interaction studies in healthy people, ecnoglutide did not change warfarin or metformin enough to need a dose change, and its effects on rosuvastatin and digoxin were studied too. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
Safety notes
In the 40-week SLIMMER phase 3 trial in China, side effects of any kind were reported by 93% on ecnoglutide and 84% on placebo, mostly mild-to-moderate GI events; ten people on ecnoglutide stopped because of side effects. In the diabetes trials, GI side effects came mainly in the step-up period and faded, there was no severe low blood sugar, and pulse rose slightly, as with other GLP-1 drugs; a rise in the lab value lipase was more common than on placebo (about 12% vs 3%), worth knowing if a blood test shows it. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
Goes with.
One question at a time.
Compared with.
Mixing charts by vial size.
Studies, in plain English.
- Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis
- Ecnoglutide: HbA1c fell up to 2.43% at 24 weeks in EECOH-1
- Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutide
- Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg arm
- Ecnoglutide: HbA1c fell up to 2.39% at 20 weeks in type 2 diabetes
- Ecnoglutide: well tolerated weekly for 6 weeks in a phase 1 trial
- Every study on Ecnoglutide
Questions people ask.
What is Ecnoglutide?
A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased". In its phase 3 obesity trial, the 2.4 mg dose took off about 13% at 40 weeks and about 15% at 48 weeks.
How is Ecnoglutide dosed in research?
The research range for Ecnoglutide is 0.6–2.4 mg, weekly, with a 0.3 mg starting dose. Studied in research — not a recommendation.
How long does Ecnoglutide last?
The half-life of Ecnoglutide is ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026).
What do people report on Ecnoglutide?
Commonly reported on Ecnoglutide: appetite control and early GI side effects, much as with semaglutide. It is not FDA-approved.
Is Ecnoglutide safe?
The research basis for Ecnoglutide is established: clinical trials or FDA-approved use exists. Common side effects in the library: decreased appetite, diarrhea, nausea, abdominal bloating and weakness.
What does Ecnoglutide stack with?
Common stacks for Ecnoglutide: BPC-157 (GI support).
Research.
Reference.
- Cadence
Weekly
- Half-life
~5.5 days
~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026)
- Research basis
●●●
EstablishedClinical trials or FDA-approved use exists
Reviewed How we check the library
